(***) Products for Pain: Ineffective, Expensive, and With Potential Harms

[Deleted member 43589]

Well folks, This pretty well sums up what I believe after using quite a few different product to relieve pain.

Highlights​

• •
  Cannabidiol (***) products have varying amounts of ***, from none to much more than advertised.
• •
  *** products may contain other chemicals than ***, some of which may be harmful.
• •
  Sixteen RCTs for pain used pharmaceutical *** in oral, buccal/sublingual, and topical forms.
• •
  Fifteen of the 16 RCTs were negative: no greater pain-relieving effect for *** than for placebo.
• •
  Meta-analyses link *** to increased rates of serious adverse events and hepatotoxicity.

Abstract​

Cannabidiol (***) attracts considerable attention for promoting good health and treating various conditions, predominantly pain, often in breach of advertising rules. Examination of available *** products in North America and Europe demonstrates that *** content can vary from none to much more than advertised and that potentially harmful other chemicals are often included. Serious harm is associated with chemicals found in *** products and reported in children, adults, and the elderly. A 2021 International Association for the Study of Pain task force examined the evidence for cannabinoids and pain but found no trials of ***. Sixteen *** randomized trials using pharmaceutical-supplied *** or making preparations from such a source and with pain as an outcome have been published subsequently. The trials were conducted in 12 different pain states, using 3 oral, topical, and buccal/sublingual administration, with *** doses between 6 and 1,600 mg, and durations of treatment between a single dose and 12 weeks. Fifteen of the 16 showed no benefit of *** over placebo. Small clinical trials using verified *** suggest the drug to be largely benign; while large-scale evidence of safety is lacking, there is growing evidence linking *** to increased rates of serious adverse events and hepatotoxicity. In January 2023, the Food and Drug Administration (FDA) announced that a new regulatory pathway for *** was needed. Consumers and health care providers should rely on evidence-based sources of information on ***, not just advertisements. Current evidence is that *** for pain is expensive, ineffective, and possibly harmful.

Perspective​

There is no good reason for thinking that *** relieves pain, but there are good reasons for doubting the contents of *** products in terms of *** content and purity.

https://www.jpain.org/article/S1526-5900(23)00582-5/fulltext

 

[Alspersk]

It's crucial to have honest discussions about *** products, especially when it comes to pain relief. The inconsistency in *** content and the presence of potentially harmful chemicals are definitely concerning.